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ABSTRACT
The antibiotic vancomycin was developed by Eli Lilly in the 1950s in response to
the growing number of Staphylococcus aureus infections that were resistant to penicillin.
Vancomycin was not widely used at the time because of its high toxicity. However, use
of vancomycin in the United States has increased dramatically since the 1980s because of
the emergence of methicillin resistant Staphylococcus aureus (MRSA) and Enterococcus
species. There are three known mechanisms for vancomycin resistance: 1) target site
modification by van genes, 2) biofilm formation, and 3) bacterial cell wall thickening. Of
these mechanisms, target site modification is the most common. In this study, we
analyzed cultivable highly vancomycin-resistant Gram-positive bacteria from the saliva
of migratory songbirds, which were captured at the bird banding station at Fort Hays
State University in previous work. Individual bacterial isolates were identified by partial
16S rRNA sequencing. The majority of the identified bacteria were Staphylococcus
succinus, with the majority being isolated from American Robin, which is commonly
found in all of North America. Some of these bacteria carry vanA, vanB, and vanC genes
and also have the ability to form biofilms. One of the van gene-carrying isolates is also
coagulase-positive which is also considered a strong virulence factor. Given the wide
range of the American Robin and ease of gene transfer between Gram-positive cocci, we
postulate that these organisms could serve as a source of vancomycin resistance genes in
human pathogens.
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INTRODUCTION
Vancomycin
Vancomycin, which is classified as a member of the glycopeptide antibiotic group,
was isolated from Streptomyces orientalis by Eli Lilly and Company in 1952. They
started clinical trials for vancomycin in human subjects and concluded that it was very
effective against penicillin-resistant bacteria. Unfortunately, they also detected high
toxicity of vancomycin to humans. The observed symptoms of vancomycin toxicity
included ototoxicity, venous irritation, chills, and rash, which were thought to be largely
due to impurities of vancomycin in those early preparations. Rapid infusion of
vancomycin also caused “red man” or “red neck” syndrome which is characterized by a
combination of erythema, pruritis, hypotension, and angioedema. By contrast, methicillin,
the first semisynthetic penicillin, was less toxic than vancomycin, so vancomycin was
reserved only for patients with severe infections (Levine, 2006).
The target site of vancomycin against bacteria is the dipeptide, D-Ala-D-Ala, on
the pentapeptide within the peptidoglycan layer. Transpeptidase produced by bacteria
recognizes the dipeptide (D-Ala-D-Ala) at the end of the pentapeptide chain, cleaves off
the terminal alanine, and joins the remainder to the branch of a stem peptide from an
adjacent polysaccharide chain. In another words, the transpeptidase is responsible for
finalizing bacterial cell wall synthesis. Inhibition of this process by vancomycin leads to
the destruction of the bacterial cell by osmotic pressure (Figure 1).
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Vancomycin Resistance - van Genes
One of the major resistance mechanisms bacteria use against vancomycin is the
vancomycin-resistance genes, which are called van genes. There are six well
characterized van genes: vanA, vanB, vanC, vanD, vanE, and vanG. Bacteria carrying
vanA, vanB, and vanD confer high levels of Minimum Inhibitory Concentration (MIC)
against vancomycin. MIC is the term used to describe the lowest amount of antibiotic
required to kill or inhibit organisms. Furthermore, vanA and vanB achieve very high
vancomycin resistance (MIC= up to 1000 mg/L) (Courvalin, 2006). It has also been
shown that the vanA gene also has the ability to confer high resistance to another member
of the glycopeptide antibiotic group, teicoplanin (MIC= up to 512 mg/L) (Courvalin,
2006). What vancomycin resistant organisms do is to change the sequence of the D-AlaD-Ala to D-Ala-D-Lac or D-Ala-D-Ser to prevent vancomycin binding (Figure 2). This
decreases the affinity between the vancomycin and the dipeptide. The affinity between
vancomycin and the precursor dipeptide D-Ala-D-Lac (for vanA, vanB, and vanD) is
1000-fold lower than for the precursor dipeptide D-Ala-D-Ala. In the case of vanC, vanE,
and vanG, the affinity between vancomycin and precursor dipeptide D-Ala-D-Ser is 6fold lower than for the precursor dipeptide D-Ala-D-Ala (Hong et al, 2008). Due to the
much lower affinity, vanA, vanB, and vanD genes produce high levels of vancomycin
resistance. Furthermore, the expression of vanA and vanB genes is inducible, and is the
most frequently encountered type of glycopeptide resistance (Courvalin, 2006). The
genes vanA, vanB, vanC, vanD, vanE, and vanG, are responsible for ligase function,
which connects the amino acids and synthesizes dipeptide in the pentapeptide of

3
peptidoglycan layer. These vancomycin-resistance genes are only part of a key set of
genes required to change the sequence of the dipeptide within the pentapetide. In other
words, the existence of those van genes, vanA, vanB, vanC, vanD, vanE, and vanG, alone
cannot change the sequence of dipeptide. The vancomycin-resistant bacterial strains
usually carry a cluster of resistance genes which function to change the sequence of
dipeptide targets. The main resistant genes which achieve the change of dipeptide
sequence are vanH, which produces a dehydrogenase that converts pyruvate to D-Lac,
vanA (or other ligase producing gene such as vanB) which catalyzes the formation of an
ester bond between D-Ala and D-Lac, and vanX, a D,D-dipeptidase which hydrolyzes the
dipeptide D-Ala-D-Ala synthesized by the host Ddl ligase enzyme (Figure 3) (Courvalin,
2006).
These are common genes in vancomycin-resistance operons, but the resistance
genes themselves in each operon are different. For instance, the vanB gene operon has
vanW gene of unknown function, which the vanA operon does not carry (Figure 4).
However, the most significant difference between the bacteria carrying the group of vanA
and vanB operon and the vanD operon is the control of expression. Both the vanA and
vanB operons are inducible, while the vanD operon is constitutive (Depardieu et al,
2004a).
Another difference between the group of vanA- and vanB- versus vanD- type strains is
lack of D,D-dipeptidase activities. The vanA- and vanB-type strains require vanX
activity to hydrolyze the dipeptide D-Ala-D-Ala synthesized by the host Ddl ligase, but
the vanD-type strains do not require the vanX activity since the chromosomal ddl gene is
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mutated, which means absence of an active D-Ala:D-Ala ligase. Consequently, the vanDtype strains should grow only in the presence of vancomycin since they rely on the
inducible resistance pathway for peptidoglycan synthesis (Figure 5) (Depardieu et al,
2004a).

Vancomycin Resistance-Biofilms
Another major vancomycin-resistance mechanism in some bacteria is biofilm
formation, which slows the penetration of antibiotics to the cytoplasm of the bacterial cell.
(Stewart, 2002 and Dunne et al, 1993). Biofilm formation is also known as one of the
most threatening virulence factors researched by microbiologists because biofilmembedded bacteria are more resistant to antimicrobial agents and often cause chronic
infections and sepsis in immunocompromised patients (Schlag et al, 2007). A major
complication of biofilm formation is device-related infections, which are serious clinical
problems today. The majority of hospital patients undergo procedures for the insertion of
foreign devices, such as catheters, artificial heart valves, and joint replacements. Devicerelated infections cause significant problems since the biofilm-embedded bacteria have
resistance against many antimicrobial agents (Stewart, 2002).
In the case of Staphylococcus aureus, the biofilm is created by polysaccharide
intercellular adhesin (PIA) which leads the bacteria to attach to, and accumulate on, host
tissues. Some bacteria involve other components to form biofilm. The control of biofilm
formation is basically regulated by the quorum sensing mechanism, which allows bacteria
to detect the density of their own species. Quorum sensing has also been shown to control
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the stability of the three-dimensional biofilm structure (Bjarnsholt and Givskov, 2007).
There are several advantages to the formation of biofilm by bacteria. First, bacteria
embedded within biofilm are basically surrounded by exopolymer substance matrix
(EPS) which creates pools of genes allowing for genetic acquisition and exchange by
horizontal transfer, which leads to alteration of gene expression of bacteria within the
biofilm, allowing them to become resistant to antibiotics. The EPS protects the bacteria
inside the biofilm from attack by antibiotics. Furthermore, a decrease of bacterial growth
within the biofilm increases resistance to antibiotics, enhancing survivability.
(Clutterbuck et al, 2007). Scientists have researched the mechanisms of biofilm formation
because many genes are involved in the process. The genes related to biofilm formation
are different between various bacterial strains, so that biofilm formation is a very
complex process.
Quorum sensing is also related to autolysis, which is responsible for the
destruction of the cell wall and subsequent cell lysis. Biofilm formation requires
extracellular DNA (eDNA) for stability and development. Autolysis destroys the
bacterial cell wall, leading to the release of eDNA from the dead cell, which is
subsequently used for construction of the biofilm by the living cells that remain (Rice et
al, 2007). Autolysis also plays a role in cell wall thickening, which is another mechanism
used by some bacteria to resist vancomycin (Gazzola and Cocconcelli, 2008).
The cell wall thickening process basically thickens the peptidoglycan layer in the
bacterial cell. For Gram-positive bacteria, the peptidoglycan layer is composed of glycan
chains that are constructed by alternating N-acetylmuramic acid (NAM) and N-
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acetylglucosamine (NAG) subunits. Tetrapeptides, which extend from the NAM subunits
of the glycan chains, act as anchor points for peptide interbridges, allowing the glycan
chains to be linked together to form a three-dimensional meshwork (Hiramatsu, 2001).
According to Sieradzki and Tomasz, some vancomycin-resistant Staphylococcus aureus
(VRSA) strains stop the autolysis process in the presence of vancomycin, so the cell wall
becomes thickened (1997). In this work, investigators cultured VRSA in growth media
containing vancomycin to measure the decrease of the vancomycin concentration during
bacterial growth. According to these experiments, the concentration of the vancomycin in
the media decreased gradually as the bacterial growth increased (Sieradzki and Tomasz,
1997). According to Cui et al (2006), the thickness of cell wall for vancomycinintermediate Staphylococcus aureus (VISA) strain Mu50, was 35.02 nm, which is 1.64
times thicker than the cell wall of vancomycin-susceptible Staphylococcus aureus
(VSSA). It was demonstrated that vancomycin clogs the bacterial peptidoglycan layer,
which prevents further penetration of subsequent vancomycin molecules (Cui et al, 2006).
The thickening cell wall correlates with an increase of vancomycin MIC. These
investigators also detected that the vancomycin MIC of those strains decreased under the
vancomycin-free environment (Cui et al, 2003). Some of the VRSA strains lost the
vancomycin-resistance phenotype under the antibiotic-free condition so these workers
postulated that these bacteria somehow use the vancomycin (Cui et al, 2003).

Vancomycin-Resistant Pathogens- VRE and VRSA
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Two of the major pathogenic groups of bacteria that exhibit vancomycin
resistance are vancomycin-resistant enterococci (VRE) and vancomycin-resistant
Staphylococcus aureus (VRSA). A certain type of VRE is called vancomycin-dependent
Enterococcus (VDE) because it requires vancomycin for cell wall synthesis.
Vancomycin-resistant strains usually change the amino acid structure of their cell walls to
avoid the interaction between vancomycin and the cell wall components, which
essentially leads to vancomycin inactivation (Bambeke et al, 1999). In other words, VDE
strains cannot survive without vancomycin because of mutation of the ddl gene. As
mentioned previously, the chromosomal ddl gene is responsible for D-Ala:D-Ala ligase
function which synthesizes the dipeptide for bacterial cell walls. Mutation of the
chromosomal ddl gene means inactivation of synthesis of the dipeptide for bacterial cell
wall formation. In another words, the bacteria cannot synthesize bacterial cell walls
unless other genes synthesize the bacterial cell wall dipeptide, replacing the function of
the defective ddl gene. Consequently, VDE strains substitute the dipeptide, D-Ala-D-Lac
or D-Ala-D-Ser, synthesized by van genes for bacterial cell wall synthesis since
vancomycin activates van genes (Bambeke et al, 1999). Another phenomenon similar to
vancomycin dependence in VDE has been reported by Dantas et al who demonstrated
some bacteria have the ability to survive on antibiotics as their sole carbon sources (2008).
Another serious vancomycin-resistant organism is vancomycin-resistant
Staphylococcus aureus (VRSA), which is related to methicillin-resistant Staphylococcus
aureus (MRSA). Methicillin was introduced in Europe in 1959 and in the United States
in 1961, and the first reported case of MRSA was in the United Kingdom in 1961. The
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first reported case of MRSA in the United States was in 1968. MRSA is currently known
as one of major pathogens in hospitals all over the world (Rice, 2006). According to a
meta-analysis report in 2008, the overall mortality rate caused by MRSA infection was
over 50%. In two of those analysis cases, it was over 70% (Dancer, 2008). In the United
States, 59.5% of ICU patients were infected with MRSA according to the National
Nosocomial Infections Surveillance (NNIS) system report for 2004. Furthermore, that
number represented an 11% increase of MRSA infections during the period 1998 to 2002
(Rice, 2006). Vancomycin is currently the drug of choice for MRSA infections, but the
use induces emergence of VRSA and vancomycin intermediate Staphylococcus aureus
(VISA) (Jones, 2008).
The first reported case of VRSA was in 1996 in Japan. In the United States, the
first four cases of VISA were reported between 1997 and 1999 (Rice, 2006). The
mortality rate of the patients who acquired VISA was 63% (Dancer, 2008). A main
difference between VISA and VRSA is the MIC. The MIC of vancomycin against VISA
strains is 8 to 16 mg /L, whereas in the case of VRSA it is 64 mg/L. Another main
difference is the mechanism of resistance against vancomycin. For VISA strains, the cell
wall thickens, which causes it to trap the vancomycin molecule in the outer layer of the
cell wall, thereby limiting access to the cytoplasmic membrane where the functional
targets of vancomycin are located. In the case of VRSA strains, the organisms carry
vancomycin resistance genes such as vanA, which produces an enzyme to change the
dipeptide sequence of bacterial cell wall, and involves horizontal transfer of transposons
from VRE (Rice, 2006).
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Both MRSA and VRSA originally came from Staphylococcus aureus which can
inhabit the surface of human skin or nasal passages as normal flora. VRSA strains carry
vancomycin resistance genes, and MRSA strains carry many antibiotic resistance genes.
Many of today’s MRSA strains have tolerance to vancomycin. Staphylococcus aureus
produces many toxins such as α-toxin, staphylococcal toxic shock syndrome toxin
(STSST), enterotoxins, and Panton-Valentine leucocidin (PVL). For instance, PVL
strains cause specific human infections such as necrotizing pneumonia, where the
mortality rate is up to 75%. Furthermore, some of these toxins are enhanced by use of
certain antibiotics such as members of the ß-lactamase antibiotic group (Dancer, 2008).
Normally, infections caused by Staphylococcus aureus are treated by antibiotics, but it is
difficult to treat with antibiotics if the infection is caused by MRSA, since MRSA is
resistant to many antibiotics. Furthermore, it has been reported that certain MRSA strains
are resistant to the newest antibiotic, linezolid (Arias et al, 2008). According to that
report, a 52-year-old female acquired a MRSA infection during a surgical procedure, and
the hospital prescribed six different antibiotics which are relatively powerful antibiotics.
However, the patient died of the infection at day 27 because of multi-organ failure (Arias
et al, 2008). There are two key antibiotics used in the treatment of MRSA infections:
vancomycin and linezolid. Although linezolid is one of the newest antibiotics, MRSA
quickly became resistant to it according to that report (Arias et al, 2008). Due to the
ability to rapidly develop tolerance to new antibiotics, and to produce many types of
toxins, MRSA is currently known as one of the most serious pathogens in hospitals.
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Coagulase-Negative Staphylococci
Staphylococci are conveniently divided into two groups based on the production
of the enzyme coagulase. These are called coagulase-positive staphylococci (CPS) and
coagulase-negative staphylococci (CNS). Coagulase is the enzyme that acts with a blood
plasma factor to convert fibrinogen to a fibrin clot (Ryan and Ray, 2010). Staphylococcus
aureus, including MRSA, is classified as a CPS. The CNS organisms are known as starter
cultures for fermented food products and as opportunistic pathogens rather than as frank
pathogens. For instance, Staphylococcus succinus and Staphylococcus equorum are both
classified as CNS and are either associated with foods, or play a major role in the food
processing industry. One of main advantages of starter cultures in food processing is that
the fermentation and the ripening process can be carried out under controlled conditions
(Zell et al, 2008). The CNS organisms are also known as normal flora of warm-blooded
animals such as birds and mammals, including humans (Irlinger, 2008 and Place et al,
2002). For this reason, most CNS strains are thought of as being beneficial
microorganisms rather than virulent pathogens.
However, some CNS strains can cause severe infections, especially in
immunocompromised people, and are often difficult to treat because they are relatively
antibiotic-resistant (Zell et al, 2008). For example, the oxacillin resistance of CNS lies
between 70% and 80% according to reports from different parts of Europe (Diekema et al,
2001). Similar rates were also observed in the USA, Canada, and Latin America. In a
report by Dar et al, it was shown that 22.5% of CNS isolates from 750 human subjects
were resistant to methicillin (2006). Furthermore, an antibiotic-induced SOS response
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promotes horizontal dissemination of pathogenicity island-encoded virulence factors in
staphylococci (Ubeda et al, 2005). Those virulence factors include toxins such as
hemolysins α,ß,γ, and δ, leukocidin, exfoliative toxins A and B, toxic shock syndrome
toxin-1 (TSST-1), and a family of emetic pyrogenic superantigens (Zell et al, 2008).
In previous work in our lab, sixteen Gram-positive vancomycin-resistant cocci
strains were isolated from the oral cavities of birds caught at the bird banding station on
the campus of Fort Hays State University. These birds included eight American Robins
(Turdus migratorius), three Orange-Warblers (Vermivora celata), and one each of
Carolina Wren (Thryothorus ludovicianus), Least Flycatcher (Empidonax minimus),
Swainson’s thrush (Catharus ustulatus), and Mourning warbler (Oporornis philadelphia)
(Bitner, 2008).
Those bacterial isolates were identified from the partial sequencing of the 16S
rRNA gene. The closest match to fourteen of the isolates was Staphylococcus succinus
AF004219, while the closest matches to the other two isolates were Staphylococcus
saprophyticus and Enterococcus gallinarum. The MIC of vancomycin isolates was ≥ 256
µg /mL, and three of the isolates were shown to be coagulase-positive by the tellurite
glycine agar method (Bitner, 2008).
In this study, I assayed those sixteen previously isolated Gram-positive
vancomycin-resistant cocci for the presence of van genes and the ability to produce
biofilm. I found van genes, vanA, vanB, and vanC in several of these organisms. In
addition, some of the isolates were also shown to have the ability to produce biofilm,
which may be considered a significant virulence factor. However, the CNS strains are
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usually not major pathogens, as mentioned earlier. A major concern of the CNS strains is
that they could transfer virulence factors to other bacteria by horizontal gene transfer,
leading to wide dispersal. Since the CNS are staphylococci, the virulence factors could be
easily transferred to other more virulent Staphylococcus strains, such as MRSA.
Another major concern raised by this study is that the vancomycin-resistant
organisms were isolated from birds that are commonly found all over North, Central, and
parts of South America (Aldrich and James, 1991). The extensive habitat of these animals
could allow them to serve as vectors to widely disseminate vancomycin-resistance genes
in the environment. To the best of my knowledge, this is the first report of van genes
being found in a staphylococcal species other than Staphylococcus aureus and the first
report of vanB in a bacterial genus other than Enterococcus.
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MATERIALS AND METHODS

Organisms For This Study
I focused on the 16 vancomycin-resistant Gram-positive cocci previously isolated
from wild song birds at the bird banding station at Fort Hays State University (Bitner,
2008).

Genomic DNA Isolation
Pure cultures of the bacteria were inoculated in 4.0 mL of tryptic soy broth (Difco,
Detroit, Michigan, USA) and incubated for 12 hours at 37° C. Bacterial genomic DNA
was isolated from the overnight cultures by using the protocol from Ausbel et al. (1997).
The steps of the protocol were performed as follows: 1) 1.5 mL of overnight culture were
centrifuged at 12,000 rpm for two minutes and the supernatant was removed; 2) The
pelleted cells were resuspended in 567 µL of TE buffer (10mM Tris·Cl, and 1mM
EDTA) buffer by repeated pipetting; 3) 30 µL of 10% SDS and 3µL of 20 mg/mL
proteinase K were added into the mixture and the mixture was incubated at 37° C for one
hour; 4) 100 µL of 5M NaCl were added and mixed thoroughly and 80µL of CTAB/NaCl
solution (10% hexadecyltrimethyl ammonium bromide (CTAB)/0.7M NaCl) was added
into the mixture and the mixture was incubated at 65 °C for 10 minutes; 5) 780 µL of
chloroform/isoamyl alcohol (24:1) was added, mixed, then centrifuged at 12,000 rpm for
five minutes; 6) the aqueous (top) layer was transferred to a fresh 1.5 mL centrifuge tube
and 600 µL of phenol/chloroform/isoamyl alcohol (25:24:1) were added, mixed, and
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centrifuged at 12,000 rpm for five minutes; 7) the aqueous layer was transferred into a
fresh 1.5 mL microcentrifuge tube and 300 µL of isopropanol were added and mixed
until DNA precipitated; 8) the mixture was centrifuged at 12,000 rpm for five minutes
and the supernatant was removed; 9) the pelleted DNA was washed carefully by adding 1
mL of 70% ethanol then centrifuged at 12,000 rpm at five minutes; 10) the supernatant
was removed and the pelleted DNA was dried by vacuum centrifugation until all traces of
ethanol had been removed. The pellet was resuspended in 100 µL of sterile water and
stored at -20° C. The final product was confirmed by agarose gel electrophoresis by using
10 µL of purified DNA and 3.0 µL of orange G loading dye. A 1.0% agarose gel in 1X
TAE buffer (0.04 M Tris-Acetate and 0.001 M EDTA) was used with electrophoresis
conditions of 90 volts for one hour. Samples were run next to the 1kb DNA ladder
(Promega Corporation, Madison, Wisconsin). The agarose gel was stained with ethidium
bromide, and viewed by using the Gel Logic 100 gel documenter (Eastman Kodak
Company, Rochester, New York).

Polymerase Chain Reaction
The presence of van genes was detected by the polymerase chain reaction (PCR),
using the extracted genomic DNA as the template, and specific primers for the vanA,
vanB, vanC, and vanD genes. The primers used for PCR were EA1 (vanA forward), EA2
(vanA reverse), EB3 (vanB forward), EB4 (vanB reverse), EC5 (vanC forward), EC8
(vanC reverse), ED1 (vanD forward), ED2 (vanD reverse) (Depardieu et al, 2004b)
(Table 1). The annealing temperatures for the reactions were based on the protocol

15
followed by Depardieu et al (2004b), which was 54° C. The following components for
PCR were combined in a 0.5mL centrifuge tube: 39.5 µL sterile water, 5.0 µL standard
Taq reaction buffer, 1.0 µL deoxynucleotide solution (dNTP) mix (containing
deoxyadenosine triphosphate, deoxycytosine triphosphate, deoxyguanine triphosphate,
and deoxythymine triphosphate, each at a 10 mM concentration), 0.5 µL bovine serum
albumin, 0.5 µL Triton X-100, 0.5 µL forward primer, 0.5 µL reverse primer, 2.0 µL
template DNA, and 0.5 µL Taq DNA polymerase. The PCR reaction was performed in a
thermocycler using the following conditions: 94° C for three minutes, 40 cycles of 94° C
for one minute, 54° C for 1 minute, and 72° C for 1 minute; the final elongation step was
72° C for seven minutes.

Detection of van Genes
The presence of PCR products was verified using agarose gel electrophoresis,
using 20 µL of amplified DNA and 3.0 µL of orange G loading dye per well. A 3.0%
agarose gel in 1X TAE buffer was used with electrophoresis conditions of 90 volts for
100 minutes. Samples were run next to the 100bp DNA ladder (Promega, Corporation,
Madison, Wisconsin). The agarose gel was stained using the ethidium bromide, and
viewed by using the Gel Logic 100 documentation system (Eastman Kodak Company,
Rochester, New York). The amplified vancomycin resistance genes were compared to
positive control PCR products from bacterial strains known to carry various van genes. I
used Enterococcus faecalis SFV1 as the positive control for vanA from Dr. Susan
Flannagan at the University of Michigan (Ann Arbor, Michigan), Enterococcus faecalis
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V583 as positive control for vanB, and Enterococcus gallinarum ATCC 49579 as the
positive control for vanC from Dr. Ludek Zurek at Kansas State University (Manhattan,
Kansas).

Crystal Violet Assay
One method used for the detection of biofilm was Crystal Violet Assay (CVA)
(Toledo-Arana et al, 2001). Pure cultures of each organism were inoculated in 4.0 mL of
TSB (Difco, Detroit, Michigan, USA) and grown for 12 hours at 37°C. Staphylococcus
epidermidis ATCC 35984 and Staphylococcus epidermidis ATCC 12228 were used as
positive and negative controls respectively in this assay. The steps of the protocol were
performed as follows: 1) 200 µL of the bacterial cell suspension were used to inoculate a
well in a sterile 96-well polystyrene microtiter plate (Fisher, Hanover Park, Illinois,
USA). After 24 hours of incubation at 37°C, the bacterial suspension was removed; 2)
The wells were gently washed three times with 200 µL phosphate-buffered saline (PBS);
3) The wells were dried at 50-60° C for one hour using Isotemp Vaccum Oven Model
280A; 4) The wells were stained with 200µL of 1% aqueous crystal violet for 20 minutes;
5) The wells were rinsed with deionized water; 6) The wells were fixed by ethanolacetone (80:20, vol/vol); 7) The optical density at 550-590nm was determined using a
microtiter plate reader (Sunrise, Salzburg, Austria).

17
Scanning Electron Microscopy
Specimens were prepared for scanning electron microscopy as described in
Thurlow and Gillock (2005). Briefly, specimens were grown overnight in trypticase soy
broth at 37°C. Samples were vacuum filtered through 0.45 µm HA filters (Millipore
Corporation, Billerica, Massachusetts). Filters containing the specimens were fixed in
0.15 M cacodylate buffer and 1% glutaraldehyde overnight. Filters were washed in a
graded series of 95% ethanol and sterile distilled water for 15 minutes at each step (10%
ethanol, 25% ethanol, 50% ethanol, 75% ethanol, 100% ethanol). Samples remained in
ethanol for at least 24 hours. The filters were then dried in two steps by using
hexamethyldisalazane (HMDS) and 95% ethanol (Step 1, 50% and HMDS 50% ethanol
for 15 minutes: Step2, 100% HMDS until completely evaporated). Filters containing
specimens were cut and mounted on a brass plate by using silver cement. The brass plates
were fixed to an aluminum stub using silver cement. The specimens were coated with a
layer of gold-palladium in a Pelco sputter coater for 1 minute. Specimens were viewed
using ISI SX-30 scanning electron microscope (Topcon America Corporation, Paramus,
New Jersey).
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RESULTS
van Gene Detection by PCR
The PCR assay indicated that five of the 14 Staphylococcus succinus isolates
carried the vanA gene alone (Figure 6 and Table 2). In these organisms, PCR products of
732 bp in length were detected, clearly indicating the presence of the vanA gene. In
Figure 6, positive results from Staphylococcus succinus isolates V22 and V45 are shown.
One of the Staphylococcus succinus isolates, V46, was demonstrated to carry three van
genes; vanA, vanB, and vanC (Figure 7 and Table 2). One isolate, Enterococcus
gallinarum, or V49 appears to carry vanC alone (Figure 8 and Table 2).

Biofilm Detection
Three of 14 Staphylococcus succinus isolates from American Robin, Mourning
Warbler, and Least Flycatcher were shown to have the potential to form biofilm
according to the results of the crystal violet assay. The density of crystal violet, as
determined by absorbance at 620 nm, in the well for V56 is very similar to that of the
well for the positive control, indicating V56 has the ability to form biofilm. (Figure 9 and
Table 2). Biofilm was directly observed via scanning electron microscopy examination of
one of the 14 Staphylococcus succinus isolates (Figure 10). The negative control strain
for biofilm formation, Staphylococcus epidermidis ATCC 12228, clearly did not
demonstrate the presence of biofilm (Figure 11). Conversely, biofilm formation was
readily seen in the positive control strain for biofilm formation, Staphylococcus
epidermidis ATCC 35984 (Figure 12).
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DISCUSSION
Previous work indicated that 14 of 16 vancomycin-resistant bacterial isolates from
six different birds species were Staphylococcus succinus according to 16S rRNA
identification. One of the isolates was Enterococcus gallinarum, while the other was
Staphylococcus saprophyticus from the American Robin (Bitner, 2008).
Enterococci are a common nosocomial urinary tract and wound infection agent,
and the third most common cause of nosocomial bacteremia in the United States. Many
enterococci species are known as serious nosocomial pathogens since they can cause
endocarditis and meningitis, and show intrinsic resistance against common antibiotics
such as penicillin and fluoroquinolones. Due to the intrinsic resistance of enterococci to
common antimicrobials, vancomycin was often used for the treatment, which ultimately
led to vancomycin-resistant Enterococcus (VRE) (Cetinkaya et al, 2000). Enterococcus
gallinarum is not commonly known as a serious nosocomial pathogen. However, this
organism eventually became a vancomycin-resistant strain called vancomycin resistant
Enterococcus gallinarum (VREG) which caused a nosocomial outbreak in a Colombian
teaching hospital in 2004 (Contreras et al, 2008). In this case, the main clinical
syndromes were bloodstream infections and surgical site infections. Unfortunately,
Contreras et al could not detect the presence of any virulence-associated genes from
VREG isolated from the outbreak (2008). However, they hypothesized that the VREG
strain had the ability to produce serious infections and disseminate across the hospital
environment since the outbreak did occur. They also did not detect the presence of any of
the virulence factors from Enterococcus faecalis and Enterococcus faecium so they
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suggest that VREG strains or unexplored pathogens carry virulence genes and facilitate
horizontal transfer of antimicrobial resistance genes across bacterial populations
(Contreras, 2008). Another study suggested that Enterococcus gallinarum might be the
original strain which carries the vanC gene intrinsically because of the degree of identity
of the sequence (Gholizadeh and Courvalin, 2000) so that Enterococcus gallinarum from
this study is not rare. However, the MIC against vancomycin of this isolate from this
study was shown to be ≥ 256 µg/mL, which means that this isolate should have other
mechanisms to tolerate such a high amount of vancomycin, since the usual resistance
capability of vanC-carrying organisms is 2-32 µg/mL (Cetinkaya et al, 2000).
One vancomycin-resistant isolate from this study was Staphylococcus
saprophyticus, which is classified as a CNS, and is usually considered normal microflora,
but can also cause medical risk. Staphylococcus saprophyticus may contribute to sausage
aroma formation and help to prevent off-flavor during normal sausage ripening, but this
strain also causes acute urinary tract infection (UTI) (Irlinger, 2008) and can be an agent
of nosocomial and bloodstream infections (Zell et al, 2008). This strain accounts for up to
42% of all UTI in young women (Eiff et al, 2002). Several studies have reported that
some Staphylococcus saprophyticus strains are vancomycin-resistant (Alamo et al, 1999).
To my knowledge, however, this is the first report of a Staphylococcus saprophyticus
strain which carries the vanA gene and has a vancomycin MIC of ≥ 256 µg/mL.
Most of the vancomycin-resistant bacterial isolates previously found in wild
songbirds by Bitner were Staphylococcus succinus (2008). This microorganism is
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normally associated with foods or plays a major role in the food processing industry, and
is not usually considered a pathogen (Resch et al, 2008).
However, the opportunistic CNS can cause severe infections since they are
relatively muti-drug resistant, as mentioned previously. In a study by Resch et al, they
chose 21 antibiotics for assessment of resistance in the CNS organimsms Staphylococcus
succinus and Staphylococcus xylosus (2008). They showed 90% of the assayed strains of
these organisms exhibited resistance to the chosen antibiotics. Furthermore, some of the
Staphylococcus succinus strains were resistant to up to four different antibiotics.
However, none of their Staphylococcus succinus strains were resistant to vancomycin.
They also observed differences in antibiotic resistance in CNS organisms isolated from
different foods. Of the CNS organisms isolated from foods, 87% of those from hard and
soft cheeses, 83% from sausage, and 93% from meat starter cultures exhibited high levels
of resistance, whereas only 19% of the CNS organisms isolated from fermented fish were
resistant (Resch et al, 2008). These investigators could not determine what factors affect
the tolerance of antibiotic resistance in different foods. The MIC against vancomycin of
most of the Staphylococcus succinus strains from this study was ≥ 256 µg/mL, indicating
they are clearly vancomycin resistant, since the NCCLS (National Committee for Clinical
Laboratory Standards) considers vancomycin-resistant microorganisms are those in
which the MIC is above 32 µg/mL (Walsh and Howe, 2002).
Furthermore, some of the isolates in my study were found to be carrying either
vanA, vanB, or vanC. The vanA and vanB resistance genes are both inducible and have
only been reported to exist in plasmid DNA (Courvalin, 2006). vanA overcomes
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vancomycin up to 1000 µg/mL and teicoplanin, in the same antibiotic group of
vancomycin, up to 512 µg/mL, whereas vanB overcomes vancomycin up to 1000 µg/mL
and teicoplanin up to 1 µg/mL (Gholizadeh and Courvalin, 2000). As mentioned in the
introduction section, vancomycin is one of the critical antibiotics for today’s antibiotic
treatment, but the high MIC of these resistant organisms are absolutely toxic for human
since vancomycin is a strong antibiotic with many potential side effects. The ingestion of
18.0-47.0 µg/mL of vancomycin during treatment was observed to cause tinnitus, rash,
neutropenia, and possible nephrotoxicity as side effects (Levine, 2006).
Three isolates from my study were shown to cause biofilm formation by CVA,
which is known as a serious virulence factor because biofilm treatment is limited and is
the leading cause of infection related to implanted medical devices (IMDs) (McCann et al,
2008). The biofilm adheres to abiotic objects such as IMDs and functions to cover the
bacteria so that they can grow on the surface of the objects, while avoiding the host
immune system and antibiotics. In some instances, biofilm-encased bacteria are dislodged
into the circulatory system, which causes bacteremia. One of the major biofilm formation
species is Staphylococcus epidermidis. In the case of Staphylococcus epidermidis,
antibiotics might kill planktonic bacteria shed from the biofilm surface, but they fail to
eradicate those embedded within the biofilm, which can then subsequently act as a
reservoir for recurrent infection. Following antibiotic treatment, a minority of drugresistant bacteria survive that repopulate the biofilm, with the survivors becoming much
more antibiotic resistant (McCann et al, 2008). To overcome colonization and infections,
many researchers and manufacturers have explored various surface technologies using
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antimicrobial biomaterials. However, several researchers have raised concern that
antimicrobial loading into a device by coating or immersion is a major driving force for
the generation of resistance. To date, the only way to avoid the problems of creating
resistant strains is the surgical removal of biofilm-coated objects. Bacteremia caused by
biofilm-forming bacterial strains is a significant medical risk in hospitals (McCann et al,
2008). To the best of my knowledge, this is the first report of any van genes being
found in a staphylococcal species other than Staphylococcus aureus as well as the first
report of the vanB in a bacterial genus other than Enterococcus.
Another key concern raised from this study is the isolation of extremely
antibiotic-resistant organisms from highly mobile wild songbirds. The majority of birds
which carried the highly vancomycin-resistant bacteria from this study were American
Robins, which are migratory and cover most of North, and portion of Central, and parts
of Northern South America (Aldrich and James, 1991). Since many American Robins
appear to carry Staphylococcus succinus, it is conceivable that the bacterium is a normal
flora microorganism of the American Robin. If this is the case, the American Robin could
act as a vector animal to spread vancomycin-resistance genes over a wide range. Birds
acting as vector animals for pathogens are not unusual. There are numerous examples of
organisms such as bacteria, viruses, fungi, and parasites being spread over wide distances
by birds (Tsiodras et al, 2008). For instance, avian influenza and West Nile Virus (WNV)
are well known to be transported by birds. The 2009 outbreak of H1N1 influenza A is a
particularly widely publicized example. In that case, the birds were also acting as media
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animals, which facilitated the alteration of the viral antigens, causing antigenic shift, and
creating more virulent viruses (Gatherer, 2009 and Patel et al, 2010).
Since bacteria freely participate in horizontal gene transfer, it is possible that the
relatively innocuous highly vancomycin-resistant isolates from this study could transfer
resistance genes to other more virulent microorganisms such as MRSA. According to
Resch et al, CNS strains could have a high incidence of transfer of antibiotic-resistance
genes to other staphylococci because of close phylogenetic relationships (2008). MRSA
is a significant pathogenic agent in hospitals. It has had a severe impact upon the
nosocomial infection mortality rate. The average mortality rate of MRSA from metaanalysis was ~36% compared to a mortality rate of ~24% from septicemia caused by
methicillin-susceptible Staphylococcus aureus (MSSA). Furthermore, seven of the
studies quoted MRSA bacteremia mortality rates over 50%, and two of these were over
80%. In the case of the patients who are infected with vancomycin-intermediate
Staphylococcus aureus (VISA), the mortality is even higher (78%) (Dancer, 2008).
Additional research is needed to verify whether free-living wild song birds are
really vector animals for vancomycin-resistance genes and whether vancomycin-resistant
Staphylococcus succinus should be considered normal flora in the American Robin.
Further research is also required to identify and understand the mechanisms of
vancomycin-resistance used by bacteria in the absence of van genes or biofilm formation,
as was seen in isolates V47, V67, V166, V170, V183, and V186 (Table 2). It is possible
that these organisms are utilizing a cell wall thickening mechanism, or could be using a
vancomycin-resistance pathway not yet reported in the literature.
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Figure 1. Transpeptidase and the mode of action of vancomycin. Transpeptidase
recognizes the sequence D-Alanyl-D-alanine (D-Ala-D-Ala) at the end of the
pentapeptide chains, cleaves off the terminal alanine and joins the remainder to the
branch of a stem peptide from an adjacent polysaccharide chain. Vancomycin binds the
D-Ala-D-Ala terminus. This interaction blocks formation of mature peptidoglycan,
denying trandpeptidase access to its substrate. (From Hong et al, 2008).
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Figure 2. The mechanism of vancomycin-resistance in bacteria which carry van genes.
Vancomycin resistant bacteria change the sequence of dipeptide to D-Alanyl-D-Lactate
(D-Ala-D-Lac) at the end of the pentapeptide chain. This change lowers the affinity
between vancomycin and the dipeptide. (From Hong et al, 2008).
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Figure 4. vanB-type glycopeptide resistance. Top: Mechanism of synthesis of
peptidoglycan precursors in a vanB-type resistant strain. Bottom: vanB-type glycopeptide
resistance operon (From Courvalin, 2006).
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Figure 5. vanD-type strain and vancomycin-dependent strain. Top: Synthesis of
peptidoglycan precursors in a vanD-type resistant strain. Bottom: Organization of the
vanD operon. Due to the inactivation of the host chromosomal D-Ala-D-Ala ligase (Ddl),
the presence of vancomycin in the culture medium is required to induce expression of the
resistance pathway, thus allowing cell wall synthesis (From Courvalin, 2006).
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1,500 bp
1,000 bp
vanA (732 bp)

Figure 6. Agarose gel showing PCR detection of the vanA gene. Lane1) 100 bp DNA
ladder, Lane 2) Enterococcus faecalis SFV1 as positive control of vanA, Lane3)
Staphylococcus saprophyticus isolate V22, Lane 4) Staphylococcus succinus isolateV45.
The bands in 100 bp ladder are (starting from the top):1,500, 1,000, 900, 800, 700, 600,
500, 400, 300, 200, and 100 bp.
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Figure 7. Agarose gel showing PCR detection of the vanB gene. Lane 1) 100bp DNA
ladder, Lane 3) Enterococcus faecalis V583 (Positive control), Lane 5) Staphylococcus
succinus isolate V46.
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Figure 8. Agarose gel showing PCR detection of the vanC gene. Lane 1) 100 bp DNA
ladder, Lane 4) Enterococcus gallinarum ATCC 49579 (Positive control), Lane 7)
Enterococcus gallinarum isolateV49.
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Isolate V56

(-) Control

Absorbance
at 620nm

Isolates

V56

V154

V163

Trial1
Trial 2

0.840
0.801

0.688
0.631

0.717
0.647

(+) Control
ATCC
12228
0.177
0.162

ATCC
35984
0.632
0.647

Figure 9. Crystal Violet Assay for determination of biofilm formation. In this assay,
Staphylococcus epidermidis ATCC 122288 was used as the negative control and
Staphylococcus epidermidis ATCC 35984 was used the positive control. Staphylococcus
succinus isolate V56 (indicated in the upper left well) clearly demonstrates biofilm
formation. The table shows the absorbance of each well at 620nm. From this result, the
isolate V56, isolate V154, and isolate V163 clearly form biofilm since the absorbance
values of those wells are similar to the absorbance of ATCC 35984.
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2.0µm

Figure 10. Scanning electron micrograph of Staphylococcus succinus isolate V56. The
micrograph was taken at 3,800 X magnification. From this micrograph, V56 clearly
forms a biofilm which covers the cocci-shaped bacterial cells. Scale bar equals
approximately 2.0µm.
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Figure 11. Scanning electron micrograph of the biofilm negative control strain,
Staphylococcus epidermidis ATCC 12228. The micrograph was taken at 10,100 X
magnification. From this micrograph, no biofilm structure is observed. Scale bar equals
approximately 2.0µm.
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Figure 12. Scanning electron micrograph of the biofilm positive control strain,
Staphylococcus epidermidis ATCC 35984. The micrograph was taken at 10,500 X
magnification. From this micrograph, ATCC 35984 clearly forms a biofilm which covers
the cocci-shaped bacterial cells. Scale bar equals approximately 2.0µm.
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Gene
vanA
vanB
vanC
vanD

Primer
EA1(Forward)
EA2 (Reverse)
EB3 (Forward)
EB4(Reverse)
EC5(Forward)
EC8(Reverse)
ED1(Forward)
ED2(Reverse)

Sequence (5’-3’)
GGGAAAACGACAATTGC
GTACAATGCGGCCGTTA
ACGGAATGGGAAGCCGA
TGCACCCGATTTCGTTC
ATGGATTGGTACTGGTAT
TAGCGGGAGTGACCAGTAA
TGTGGGATGCGATATTCAA
TGCAGCCAAGTATCCGGTAA

Table 1. Table showing the primers used for the PCR detection of the van genes in this
study (From Depardieu 2004b).
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Bacteria
Species
Staphylococcus
saprophyticus
Staphylococcus
succinus
Staphylococcus
succinus
Staphylococcus
succinus
Enterococcus
gallinarum
Staphylococcus
succinus
Staphylococcus
succinus
Staphylococcus
succinus
Staphylococcus
succinus
Staphylococcus
succinus
Staphylococcus
succinus
Staphylococcus
succinus
Staphylococcus
succinus
Staphylococcus
succinus
Staphylococcus
succinus
Staphylococcus
succinus

MIC
( µg/mL)
≥ 256

Bird species

van genes

Biofilm

American Robin

A

+

≥ 256

American Robin

A

≥ 256

American Robin

A, B, and C

≥ 256

American Robin

≥ 256

American Robin

C

≥ 256

American Robin

A

≥ 256

American Robin

+

≥ 256

American Robin

1.5

Carolina Wren

-

A

≥ 256

Least Flycatcher

V154

-

-

+

1.7

Mourning Warbler

+
+

V187

≥ 256

V186

-

+

2.0

Orange-crowned
Warbler
Orange-crowned
Warbler
Orange-crowned
Warbler
Swainson’s Thrush

-

V183

-

≥ 256

Swainson’s Thrush

Isolate
Number
V22

Coagulase

V45
V46
V47
V49
V54
V56
V67
V185
V163

V166
V170

-

≥ 256
≥ 256

-

A

-

-

-

Table 2. Summary of results showing species of vancomycin-resistant bacteria,
isolate number, presence of coagulase activity, MIC of vancomycin activity, bird species
the bacteria were isolated from, type of van genes detected, and presence of biofilm.

